Showing results (181-190 of 199) with videos related to

Sort By:
Pageof 20
The Lancet. Haematology|July 23, 2019
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trialMaria-Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, et al.
Nature Medicine|February 23, 2021
Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencingYael C Cohen, Mor Zada, Shuang-Yin Wang, et al.
Annals of Hematology|January 27, 2022
Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL-a matched cohort analysisIrit Avivi, Chava Perry, Yafit Segman, et al.
British Journal of Haematology|July 10, 2018
High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMOIrit Avivi, Luca Arcaini, Virginia V Ferretti, et al.
Blood|September 12, 2022
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agentsAdam D Cohen, María-Victoria Mateos, Yael C Cohen, et al.
Bone Marrow Transplantation|January 4, 2024
Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroidsOlalekan O Oluwole, Edouard Forcade, Javier Muñoz, et al.
British Journal of Haematology|July 23, 2021
Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphomaOlalekan O Oluwole, Krimo Bouabdallah, Javier Muñoz, et al.
American Journal of Hematology|February 13, 2020
Real-world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Greco-Israeli collaborative myeloma working groupEirini Katodritou, Efstathios Kastritis, Moshe Gatt, et al.
Cancers|September 9, 2023
Outcome of Second Primary Malignancies Developing in Multiple Myeloma PatientsIrit Avivi, David H Vesole, Julio Davila-Valls, et al.
The Lancet. Haematology|January 16, 2019
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a studyAnas Younes, Joshua Brody, Cecilia Carpio, et al.
Pageof 20